Kaposi sarcoma (KS) continues to pose a significant clinical challenge for people living with HIV, even when patients maintain long-term viral suppression through antiretroviral therapy. Recent research published in HIV Medicine indicates that while chemotherapy remains an effective treatment for active KS, recurrence occurs in nearly half of patients with well-controlled HIV, suggesting that viral suppression alone is not always sufficient to prevent disease relapse.
Prospective Outcomes in Virally Suppressed Patients
Bacquart and colleagues tracked 18 patients living with HIV who maintained a viral load below 200 copies/mL for at least one year. Between June 2021 and January 2023, the French Cancer HIV network monitored these individuals, who had a median age of 49 and were predominantly male. The study found that 15 of these participants had a history of at least one prior KS relapse.
Results showed a split in patient outcomes. Seven participants achieved a partial response to chemotherapy and remained relapse-free for a median of 16 months. Conversely, eight participants experienced a recurrence after a median of six months post-treatment. These relapses were largely localized to the skin, though one patient developed visceral disease. The data highlights that despite successful HIV management, the underlying Kaposi sarcoma herpesvirus (KSHV/HHV8) can remain active and symptomatic.
Did you know?
Kaposi sarcoma is an AIDS-defining cancer. While the incidence of KS has dropped significantly since the widespread adoption of combination antiretroviral therapy (cART), it remains a persistent threat for individuals with a history of the disease.
The Impact of Treatment Toxicity and Age
Clinicians managing KS in the HIV-positive population must balance the efficacy of chemotherapy against cumulative toxicity. The Bacquart study observed that treatment-related side effects often dictated the course of care. Three patients discontinued anthracyclines due to issues like neutropenia and anorexia, while another three stopped taxane therapy because of neuropathy.
The research also identified patterns among those who relapsed. Patients who saw their KS return were generally older and had maintained viral suppression for a longer duration compared to those who remained relapse-free. While the study’s small sample size prevents definitive conclusions, these factors suggest that age-related immune senescence or the long-term impact of KSHV may complicate recovery, regardless of how well HIV itself is controlled.
Risks of Interrupting Antiretroviral Therapy
The consequences of failing to maintain HIV viral suppression were starkly illustrated by two participants in the study who interrupted their cART. After losing virological control, both individuals were readmitted with high HIV viral loads and developed active visceral KS.
For patients with a history of KS, consistent monitoring of CD4 counts and CD4/CD8 ratios is essential. Even when HIV is well-controlled, maintaining a stable immune profile is a key indicator of long-term health stability.
Frequently Asked Questions
- Can Kaposi sarcoma return if my HIV is undetectable?
Yes. According to the study by Bacquart et al., nearly half of the participants with sustained viral suppression experienced a KS relapse, indicating that viral control of HIV does not guarantee the total elimination of KS. - Why do some patients stop chemotherapy for KS?
Treatment is often stopped or adjusted due to toxicity. Common side effects include neutropenia, neuropathy, and loss of taste (ageusia), which can become cumulative over multiple rounds of chemotherapy. - What is the primary driver of KS in HIV patients?
KS is caused by the Kaposi sarcoma herpesvirus (KSHV/HHV8). While HIV-related immune suppression makes the body more vulnerable to the virus, the virus itself remains the root cause of the tumor.
For more information on the management of HIV-related malignancies, subscribe to our clinical newsletter or explore our archive of oncology-related research updates.
Related reading